Applications of metabolomics in drug discovery and development

被引:157
作者
Wishart, David S. [1 ,2 ]
机构
[1] Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E8, Canada
[2] Univ Alberta, Dept Comp Sci, Edmonton, AB T6G 2E8, Canada
关键词
D O I
10.2165/00126839-200809050-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolomics is a relatively new field of 'omics' technology that is primarily concerned with the global or system-wide characterization of small molecule metabolites using technologies such as nuclear magnetic resonance, liquid chromatography and/or mass spectrometry. Its unique focus on small molecules and the physiological effects of small molecules aligns the field of metabolomics very closely with the aims and interests of many researchers in the pharmaceutical industry. Because of its conceptual and technical overlap with many aspects of pharmaceutical research, metabolomics is now finding applications that span almost the full length of the drug discovery and development pipeline, from lead compound discovery to post-approval drug surveillance. This review explores some of the most interesting or significant applications of metabolomics as they relate to pharmaceutical research and development. Specific examples are given that show how metabolomics can be used to facilitate lead compound discovery, to improve biomarker identification (for monitoring disease status and drug efficacy) and to monitor drug metabolism and toxicity. Other applications are also discussed, including the use of metabolomics to facilitate clinical trial testing and to improve post-approval drug monitoring. These examples show that metabolomics potentially offer drug researchers and drug regulators an effective, inexpensive route to addressing many of the riskier or more expensive issues associated with the discovery, development and monitoring of drug products.
引用
收藏
页码:307 / 322
页数:16
相关论文
共 102 条
[1]   Recent methodology in the phytochemical analysis of ginseng [J].
Angelova, Nadezhda ;
Kong, Hong-Wei ;
Van Der Heijden, Rob ;
Yang, Shih-Ying ;
Choi, Young Hae ;
Kim, Hye Kyong ;
Wang, Mei ;
Hankemeier, Thomas ;
Van Der Greef, Jan ;
Xu, Guowang ;
Verpoorte, Rob .
PHYTOCHEMICAL ANALYSIS, 2008, 19 (01) :2-16
[2]   Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis [J].
Anishetty, S ;
Pulimi, M ;
Pennathur, G .
COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2005, 29 (05) :368-378
[3]   Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry [J].
Annesley, TM ;
Clayton, LT .
CLINICAL CHEMISTRY, 2005, 51 (05) :872-877
[4]  
BAINS W, 2004, DRUG DISCOVERY WORLD, P9
[5]   MSE with mass defect filtering for in vitro and in vivo metabolite identification [J].
Bateman, Kevin P. ;
Castro-Perez, Jose ;
Wrona, Mark ;
Shockcor, John P. ;
Yu, Kate ;
Oballa, Renata ;
Nicoll-Griffith, Deborah A. .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2007, 21 (09) :1485-1496
[6]   Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts [J].
Beckonert, Olaf ;
Keun, Hector C. ;
Ebbels, Timothy M. D. ;
Bundy, Jacob G. ;
Holmes, Elaine ;
Lindon, John C. ;
Nicholson, Jeremy K. .
NATURE PROTOCOLS, 2007, 2 (11) :2692-2703
[7]   Metabolomic profiling to develop blood biomarkers for Parkinson's disease [J].
Bogdanov, Mikhail ;
Matson, Wayne R. ;
Wang, Lei ;
Matson, Theodore ;
Saunders-Pullman, Rachel ;
Bressman, Susan S. ;
Beal, M. Flint .
BRAIN, 2008, 131 :389-396
[8]   A rapid and facile method for the dereplication of purified natural products [J].
Bradshaw, J ;
Butina, D ;
Dunn, AJ ;
Green, RH ;
Hajek, M ;
Jones, MM ;
Lindon, JC ;
Sidebottom, PJ .
JOURNAL OF NATURAL PRODUCTS, 2001, 64 (12) :1541-1544
[9]  
Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802
[10]   Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension [J].
Brindle, JT ;
Nicholson, JK ;
Schofield, PM ;
Grainger, DJ ;
Holmes, E .
ANALYST, 2003, 128 (01) :32-36